Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
BörsenkürzelGRAL
Name des UnternehmensGrail Inc
IPO-datumJun 12, 2024
Gegründet am2020
CEOMr. Robert (Bob) Ragusa
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse1525 O'brien Drive
StadtMENLO PARK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94025
Telefon18336942553
Websitehttps://grail.com/
BörsenkürzelGRAL
IPO-datumJun 12, 2024
Gegründet am2020
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten